The shadow of generic competition has long loomed over copyright’s iconic drug, Viagra, raising questions about the outlook of related pharmaceutical portfolios. While early times saw impressive gains, the patent expiration has opened the door for less expensive substitutes, possibly lowering revenue and creating a real risk for investors seeking